Aligos Therapeutics, Inc. (ALGS): Total Assets
$88.53M
As of 2025-12-31
$66.33M
As of 2026-06-30
-15.5%
3-year compound annual growth
-19.7%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $88.53M | +26.3% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $70.09M | -53.7% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $151.53M | +3.3% | 2025-03-10, Balance as of period end |
| 2022-12-31 | $146.69M | -37.7% | 2024-03-12, Balance as of period end |
| 2021-12-31 | $235.37M | -11.3% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $265.30M | +81.1% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $146.52M | n/a | 2021-03-23, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $88.53M | +26.3% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $116.37M | -15.6% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $9.95M | +0.2% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $18.58M | -35.5% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $98.73M | +103.7% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $2.27B | +1.0% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $11.63M | -13.5% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $146.48M | -19.0% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $791.59M | +4.9% |
Compare ALGS, HUMA, DYAI, OTLK side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗